☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
UPTRAVI
Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag- IV) to Treat Pulmonary Arterial Hypertension
October 1, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.